Andrographolide may improve viral myocarditis by inhibiting the increase in serum TNF-α, hs-CRP and cTnI levels caused by viral myocarditis, activating the IL-10/STAT3 anti-inflammatory pathway, and inhibiting the PI3K/AKT/NF-κB pathway (Zhao et al., 2018). Here, AKT1 is linked to viral myocarditis.